Non-neural phenotype of spinal and bulbar muscular atrophy: Results from a large cohort of Italian patients by Querin, Giorgia et al.
Original Citation:
Non-neural phenotype of spinal and bulbar muscular atrophy: Results from a large cohort of Italian
patients
BMJ Publishing Group
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3182445 since: 2019-04-26T18:16:30Z
10.1136/jnnp-2015-311305
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
RESEARCH PAPER
Non-neural phenotype of spinal and bulbar
muscular atrophy: results from a large cohort
of Italian patients
Giorgia Querin,1 Cinzia Bertolin,1 Elisa Da Re,1 Marco Volpe,1 Gabriella Zara,1
Elena Pegoraro,1 Nicola Caretta,2 Carlo Foresta,2 Maria Silvano,3 Domenico Corrado,3
Massimo Iafrate,4 Lorenzo Angelini,4 Leonardo Sartori,5 Maria Pennuto,6
Alessandra Gaiani,1 Luca Bello,1 Claudio Semplicini,1 Davide Pareyson,7
Vincenzo Silani,8 Mario Ermani,1 Alberto Ferlin,2 Gianni Sorarù,1 on behalf of the
Italian Study Group on Kennedy’s disease
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
jnnp-2015-311305).
For numbered afﬁliations see
end of article.
Correspondence to
Dr Gianni Sorarù, Department
of Neurosciences,
Neuromuscular Center,
University of Padova, Padova
35128, Italy;
gianni.soraru@unipd.it
Received 18 May 2015
Revised 29 July 2015
Accepted 2 September 2015
To cite: Querin G,
Bertolin C, Da Re E, et al. J
Neurol Neurosurg Psychiatry
Published Online First:
[please include Day Month
Year] doi:10.1136/jnnp-
2015-311305
ABSTRACT
Objective To carry out a deep characterisation of the
main androgen-responsive tissues involved in spinal and
bulbar muscular atrophy (SBMA).
Methods 73 consecutive Italian patients underwent a
full clinical protocol including biochemical and hormonal
analyses, genitourinary examination, bone metabolism
and densitometry, cardiological evaluation and muscle
pathology.
Results Creatine kinase levels were slightly to markedly
elevated in almost all cases (68 of the 73; 94%). 30
(41%) patients had fasting glucose above the reference
limit, and many patients had total cholesterol (40;
54.7%), low-density lipoproteins cholesterol (29; 39.7%)
and triglyceride (35; 48%) levels above the
recommended values. Although testosterone, luteinising
hormone and follicle-stimulating hormone values were
generally normal, in one-third of cases we calculated an
increased Androgen Sensitivity Index reﬂecting the
presence of androgen resistance in these patients.
According to the International Prostate Symptom Score
(IPSS), 7/70 (10%) patients reported severe lower urinal
tract symptoms (IPSS score >19), and 21/73 (30%)
patients were moderately symptomatic (IPSS score from 8
to 19). In addition, 3 patients were carriers of an
indwelling bladder catheter. Videourodynamic evaluation
indicated that 4 of the 7 patients reporting severe
urinary symptoms had an overt prostate-unrelated
bladder outlet obstruction. Dual-energy X-ray
absorptiometry scan data were consistent with low bone
mass in 25/61 (41%) patients. Low bone mass was
more frequent at the femoral than at the lumbar level.
Skeletal muscle biopsy was carried out in 20 patients
and myogenic changes in addition to the neurogenic
atrophy were mostly observed.
Conclusions Our study provides evidence of a wide
non-neural clinical phenotype in SBMA, suggesting the
need for comprehensive multidisciplinary protocols for
these patients.
INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA), also
known as Kennedy’s disease (KD), is a rare, slowly
progressive, neuromuscular disorder. It is caused by
expansion of a polymorphic CAG repeat sequence
encoding a polyglutamine (polyQ) tract in the ﬁrst
exon of the androgen steroid hormone receptor
(AR) gene on chromosome X.1 The AR CAG repeat
ranges in size from 9 to 36 in healthy respondents
but from 38 to 68 in patients with SBMA.2–4
SBMA is characterised by loss of lower motor
neurons in the spinal cord and brainstem, leading
to progressive limb and bulbar muscle weakness
and atrophy. SBMA affects adult males with onset
usually between 30 and 50 years.5 6 PolyQ tract
length negatively correlates with age at onset
without affecting disease progression.2 7
Degeneration of posterior columns can lead to loss
of vibratory sensation in distal extremities.8
AR is expressed ubiquitously.9 On binding of tes-
tosterone or dihydrotestosterone, AR translocates
to the nucleus where it regulates the expression of
a subset of genes. In SBMA, polyQ-AR accumulates
in the nucleus, causing cell toxicity which is consid-
ered a major pathogenic mechanism.10
Nuclear inclusions of the mutated protein are a
pathological hallmark of polyQ diseases. Diffuse
nuclear and cytoplasmic polyQ-AR accumulation is
found in residual motor neurons, as well as in several
neural and non-neural tissues in SBMA.5 11 Along
with these pathological ﬁndings, non-neurological
symptoms are common in SBMA. The majority of
patients show endocrine dysfunctions mainly consist-
ing of partial androgen insensitivity.2 3 12 These
include gynaecomastia, testicular atrophy, erectile
dysfunction (ED) and decreased fertility. Abdominal
obesity, dyslipidemia and glucose intolerance are also
detected in some patients. Elevated serum creatine
kinase (CK), higher than expected for a purely neuro-
genic disease, and myogenic changes on muscle
biopsy indicate an underlying myopathy.13 14 Even if
overt cardiomyopathy has not been recognised in
SBMA,15 an increased incidence of Brugada-type
ECG changes has been recently reported in a large
Japanese population with SBMA.16
Non-neurological clinical features have not
been extensively investigated in previous reports.
The aim of the present study was a deep character-
isation of the involvement of the main androgen-
Querin G, et al. J Neurol Neurosurg Psychiatry 2015;0:1–7. doi:10.1136/jnnp-2015-311305 1
Neuromuscular
 JNNP Online First, published on October 26, 2015 as 10.1136/jnnp-2015-311305
Copyright Article author (or their employer) 2015. Produced by BMJ Publishing Group Ltd under licence. 
group.bmj.com on October 30, 2015 - Published by http://jnnp.bmj.com/Downloaded from 
responsive tissues in a large collection of patients with SBMA.
The ﬁndings highlight novel non-neural dysfunctions and a
wide phenotypic spectrum, suggesting the need for a compre-
hensive, multidisciplinary approach to SBMA.
PATIENTS AND METHODS
Patients and neurological evaluation
Seventy-three consecutive patients diagnosed with SBMA were
recruited after obtaining written informed consent. All were
Italian and followed in different centres across Italy.
Development of muscular weakness was considered the onset of
disease. Since there are no validated functional scales for SBMA,
neurological disability was evaluated according to the activity of
daily living (ADL) scale17 and the revised Amyotrophic Lateral
Sclerosis Functional Rating Scale-Revised (ALSFRS-R).18
Functional status was also assessed using the 6 Min Walk Test
(6MWT),19 which is considered a biomarker of motor impair-
ment in SBMA.20 The 6MWT was performed in patients with
and without devices.
Biochemical and hormonal analyses
Blood tests included complete blood count, total CK, fasting
glucose, glycated haemoglobin (HbA1c), total cholesterol, low-
density lipoproteins (LDL), high-density lipoproteins (HDL)
and triglycerides. Bone metabolism was investigated by serum
calcium, phosphorus, alkaline phosphatase, parathyroid
hormone (PTH) and 25-OH vitamin D determination in the
same period of the year between March and September. The
reproductive hormonal proﬁle included serum concentrations of
total testosterone, luteinising hormone (LH) and
follicle-stimulating hormone (FSH).21 Testosterone values were
multiplied for LH to determine the Androgen Sensitivity Index
(ASI) (normal values <138 U×nmol/L2).22 Prostate-speciﬁc
antigen (PSA) was also measured.
Genitourinary examination
According to the International Prostate Symptom Score
(IPSS),23 lower urinary tract symptoms (LUTS) were classiﬁed as
mild (IPSS 0–7), moderate (8–19) and severe (>19) (see online
supplementary material). Seven patients reporting severe LUTS
(IPSS>19) were further characterised by prostate volume ana-
lysis by transabdominal ultrasonography24 and videourodynamic
evaluation performed according to the International Continence
Society (ICS) recommendations.25 The results of the pressure-
ﬂow study were classiﬁed according to ICS normograms.25
Images were obtained to evaluate morphology of the bladder,
bladder neck and urethra, and vesicourethral reﬂux. The pres-
ence and severity of ED was investigated with the International
Index of Erectile Function (IIEF-15) questionnaire.26 ED was
considered as IIEF<26.26 The presence of gynaecomastia was
also recorded.
Bone densitometry
Femur and lumbar (L1–L4) dual-energy X-ray absorptiometry
(DXA) scans were performed by the same technician, with spine
phantom calibration before each examination. The mean Bone
Mineral Density (BMD) index and mean T-scores were consid-
ered. The total BMD coefﬁcient of variation was 1%.
Osteopenia was deﬁned as T-score <−1 SD, and osteoporosis as
≤−2.5 SD.27
Cardiological evaluation
Cardiological evaluation included clinical history, standard
12-lead ECG and standard two-dimensional Doppler
echocardiography. Additionally, all patients underwent a modi-
ﬁed ECG recording with right precordial leads placed to the
third intercostal space, to increase the sensitivity for
Brugada-like abnormalities. Brugada-like ST-segment and
T-wave (ST-T) abnormalities in right precordial leads were classi-
ﬁed according to the second consensus conferences on the
Brugada syndrome.28 The sodium channel blocker test was not
performed. All ECGs were evaluated by two experienced elec-
trophysiologists (DC and MS).
Muscle pathology
Twenty patients underwent muscle biopsy as part of the diagnos-
tic workup. Serial cryostat sections of fresh frozen tissue were
stained with routine histochemical reactions.29 Muscle tissue
involvement was classiﬁed according to our previous study13:
type I, neurogenic atrophy (ie, type-grouping, atrophic and
target/targetoid ﬁbres); type II, neurogenic atrophy plus one or
two myopathic changes (>3% centrally nucleated ﬁbres, vesicu-
lar nuclei, basophilic degenerating ﬁbres, lobulated ﬁbres, ﬁbre
splitting); type III, neurogenic atrophy plus three or more myo-
pathic changes. Age and ADL score at biopsy were recorded for
each patient.
Genetic analysis
Genomic DNA was extracted from peripheral blood leucocytes
using the standard salting out procedure. CAG repeats were
ampliﬁed by PCR as previously described7 and repeats fragment
sizing was performed on an ABI PRISM 3700 DNA Sequencer
(Applied Biosystems, Foster City, California, USA). The speciﬁc
length of CAG repeats was further veriﬁed via Sanger
sequencing.
Statistical analysis
Linear correlation analysis was performed using the rank linear
regression of Spearman. A Student t test and χ2 test were used
to compare patients with SBMA with control data from 60 age-
matched healthy males. The signiﬁcance level was set at
p<0.05.
The study was approved by the local Ethics Committee.
RESULTS
Patients’ ages ranged from 27 to 78 years (mean 57.3 years;
SD=10.2). The mean disease duration since disease onset,
which occurred on average at 42.26±9.4 years (range 29–64;
median=46), was 13.1±6.9 years (range 0–29; median=13).
CAG repeat numbers ranged from 43 to 52 (mean 45.87;
SD=2.56). At the time of examination, 12 (16%) patients had
no muscular weakness (ADL scale grade=0), 41 (56%) patients
had mild weakness (grade 1); 13 (18%) mild-to-moderate weak-
ness (grade 2); and 7 (10%) moderate-to-severe weakness
(grade 3). Weakness-free patients reported muscle cramps, fasci-
culations, fatigability, or had elevated serum CK. Mean
ALSFRS-R was 41±3.7 (range 30–48; median=42). Eleven
patients were unable to complete the 6MWT due to severe
walking impairment or because they were wheelchair users. The
average 6MWT distance was 356±127 m (range 107–578;
median=322).
Biochemical and hormonal data are shown in tables 1 and 2.
CK levels were slightly-to-markedly elevated in 68/73 cases
(94%). Thirty (41%) patients had fasting glucose above refer-
ence; of these, 20 also had increased Hb1Ac. Many patients had
total cholesterol (40; 54.7%), LDL cholesterol (29; 39.7%) and
triglycerides (35; 48%) above recommended levels. HDL was
below recommended levels in 50/73 (68.4%) patients, of whom
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24 had high total cholesterol. Concomitant elevated fasting
glucose and total cholesterol were observed in 15 patients
(20.5%). Seven patients were on hyperlipidaemia-correcting
medications and 10 on oral antidiabetics. No correlations were
observed between biochemical data and age, or polyQ length.
Testosterone was decreased in ﬁve cases (7%) and elevated in
seven (9%). Above reference testosterone concomitant with ele-
vated LH/FSH was observed in two cases; none had concomi-
tant reduced LH/FSH. In all cases with decreased testosterone,
LH and FSH values were normal. Both testosterone and LH
values were signiﬁcantly higher in patients than in controls
(p=0.005 and p=0.0015, respectively). The average ASI value
(LH×testosterone) in our cohort of patients was within the
normal range (135.17±99.6 U×nmol/L2) and, as expected,
higher than in controls (p=0001). However, 26 patients (35%)
showed a slightly-to-markedly increased ASI. No relations
between testosterone/ASI values and polyQ length, age at onset,
functional scores and biochemical data were found.
Genitourinary tract details are summarised in online supple-
mentary table S1. Serum PSA was increased in three patients
(4%). Based on IPSS, 21 patients (30%) were moderately symp-
tomatic and 7 (10%) reported severe LUTS. Forty-two (60%)
patients were asymptomatic/mildly symptomatic. The IPSS score
directly correlated with age (p=0.0051; see online supplemen-
tary ﬁgure S1), and inversely with ADL scale grade (p=0.018;
see online supplementary ﬁgure S2); it was otherwise unrelated
to ASI, polyQ length and biochemical tests. Three patients car-
rying an indwelling bladder catheter (aged 69–78 years) did not
ﬁll in the questionnaire. One had a diagnosis of underactive
detrusor function in the absence of cervical-urethral obstruction,
while a prostate-unrelated obstruction of the bladder outlet was
reported in the remaining two patients. Patients with severe
LUTS underwent transabdominal ultrasonography and videour-
odynamic evaluation to better deﬁne underlying mechanisms.
In this group, the median age was 66 years (52–69); all patients
had normal PSA and had not undergone prostate surgery. Two
patients were taking α-blockers. Ultrasonography demonstrated
normal or moderately hypertrophic prostate volume (median
35 cc, range 25–50). Videourodynamic evaluation indicated that
four patients had overt bladder outlet obstruction, two were in
the equivocal area and one was unobstructed. In all patients, the
cystourethrography was normal, with a competent bladder neck
regularly opening during micturition, and no vesicoureteral
reﬂux, bladder diverticulum or detrusor-external sphincter
dyssynergia.
Ten (13.6%) patients refused to ﬁll in the IIEF questionnaire.
For all remaining patients, IIEF questionnaire results pointed to
a mild-to-severe ED (mean 15.9±7.6; range 0–25). IIEF scores
were inversely correlated with age (r=−0.46; p=0.0001) but
were unrelated to ASI and polyQ length.
In 57/73 (78%) patients, a bilateral gynaecomastia was noted.
Of them, two had undergone surgery for breast reduction. Also,
the presence of gynaecomastia was unrelated to ASI and polyQ
length.
Bone metabolism and DXA scan data are summarised in
table 3. We observed 22/61 (36%) cases of lumbar and/or
femoral osteopenia, and 3 (5%) cases of femoral osteoporosis.
Low BMD was more frequent at the femoral level (20 patients)
than lumbar level (1 patient). Lumbar and femoral decreased
BMD was present in four patients. Compared with controls, a
higher number of patients with SBMA showed low BMD at the
femoral level (p=0.022). Conversely, patients with SBMA had
higher BMD and T-scores (p=0.0019 and p=0.0001, respect-
ively) at the lumbar level. Serum 25-hydroxyvitamin D deﬁ-
ciency (<50 nmol/L) was observed in 40/61 (65%) patients,
while PTH, calcium, phosphorus and alkaline phosphatase were
normal in all respondents. No difference in BMD was observed
between patients with normal LH-testosterone levels and those
Table 1 Biochemical profile of patients with spinal and bulbar muscular atrophy
Mean±SD (range; median) Reference range
Out of reference range
High Low
Biochemical analyses
Haematocrit (%) 0.43±0.02 (0.37–0.50; 0.43) 0.41–0.507 1/73 0/73
Creatine kinase (UI/L) 1095.8±823 (119–4406; 823) 20–180 68/73 0/73
Fasting glucose (nmol/L) 5.9±1.7 (3.7–14.1; 5.4) 3.7–5.6 29/73 0/73
Glycated haemoglobin (nmol/L) 38.9±8.2 (25–75; 37) 20–38 25/73 0/73
Triglycerides (mg/dL) 1.94±1.26 (0.51–9.28; 1.66) <2.11 35/73 –
Total cholesterol (nmol/L/L) 5.3±1.0 (3.32–8; 5.33) <5.18 40/73 –
High-density lipoprotein (nmol/L) 1.42±0.5 (0.32–2.86; 1.34) >1.55 – 50/73
Low-density lipoprotein (nmol/L) 3.3±0.87 (1.78–4.68; 3.2) <3.34 29/73 –
Prostate-specific antigen (mg/L) 1.17±1.18 (0.11–21.7; 0.5) <4 3/73 –
Table 2 Hormonal profile of patients with SBMA
Mean±SD (range; median)
Reference
range
Out of reference range Controls
Mean±SD
p Value of patients
vs controlsHigh Low
Total testosterone (nmol/L) 19.2±7.1 (6.79–41.88; 18) 10–29 7/73 5/73 16.2±4.4 0.005
Follicle-stimulating hormone (IU/L) 7.2±5.1 (1.2–26; 6) 1–8 23/73 0/73 6.1±3.2 ns
LH (IU/L) 6.84±3.6 (1.97–25.5; 5.9) 1–8 20/73 0/73 4.8±3.6 0.0015
ASI (LH×testosterone) (U×nmol/L2) 135.17±99.6 (21.7–619.39; 109.2) <138 26/73 – 82.7±43.8 0.0001
ASI, Androgen Sensitivity Index; LH, luteinising hormone; ns, not significant; SBMA, spinal and bulbar muscular atrophy.
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with hypogonadism (low testosterone and/or elevated testoster-
one/LH), nor between patients with normal versus deﬁcient
25-hydroxyvitamin D. Similarly, no difference was observed
between patients with normal and high ASI. DXA data were
also unrelated to functional measures, polyQ length and age.
Twenty-seven patients had hypertension and three had ischae-
mic heart disease. There was no evidence of speciﬁc structural
heart muscle disease. Three patients (4%) had Brugada-like
ECG changes. One patient showed a type 2 ‘saddleback’ pattern
in the standard V1-V2 precordial leads (fourth intercostal space;
ﬁgure 1A), which became type 1 ‘coved type’ in upward right
precordial leads (third intercostal space); in the other two
patients, Brugada ECG changes were detected only in the right
precordial leads placed in the third intercostal space and both
were non-diagnostic ‘saddleback’ patterns (types 2 and 3,
respectively).28 Other ECG alterations were identiﬁed in 15
(20.5%) patients, mostly consisting of left ventricular hyper-
trophy, pathological Q-waves (4 cases) and intraventricular con-
duction abnormalities (3 cases).
Muscle biopsies were obtained from quadriceps femoris in 19
patients and from biceps brachii in 1 (table 4). All patients who
underwent muscle biopsy showed weakness, and/or fasciculations,
and/or muscle atrophy. Eighteen of the 20 biopsies showed myo-
pathic changes together with neurogenic atrophy (ﬁgure 1B),
graded type I–III as explained in the Methods section. Myopathic
grading was unrelated to age at onset, nor to disease duration,
ADL scale or age at biopsy.
Table 3 Bone metabolism and DXA findings of patients with SBMA
Mean±SD (range; median)
Controls
Mean±SD
p Value of patients
vs controls
Bone metabolism analyses
Serum calcium (mmol/L) (reference range 2.1–2.8) 2.4±0.1 (2.19–2.69; 2.39) 2.3±0.1 ns
Serum phosphorus (mmol/L) (reference range 1–1.5) 0.97±0.14 (0.64–1.29; 0.98) 1.0±0.2 ns
Alkaline phosphatase (UI/L) (reference range 44–147) 55.7±16.5 (34–111; 52) – –
Parathyroid hormone (pg/mL) (reference range 10–60) 28.7±12.0 (5.8–63; 27.1) 33.3±15.6 ns
25-OH vitamin D (nmol/L) (reference range >50) 43.3±23.0 (8.9–133; 40.84) 37.6±28.5 ns
DXA parameters
Lumbar BMD (g/cm2) 1.19±0.19 (0.79–1.42; 1.14) 1.08±0.21 0.0019
Lumbar T-score 0.66±1.38 (−1.5–5.2; 0.45) −0.33±0.95 0.0001
Femoral BMD (g/cm2) 0.97±0.22 (0.26–1.9; 0.95) 1.02±0.19 ns
Femoral T-score −0.65±1.16 (−4.31–1.9; −0.6) −0.41±0.72 ns
Low BMD Patient number Control number p patients vs controls
Lumbar level 1/61 6/60 0.045
Femoral level 20/61 9/60 0.022
Femoral/lumbar level 4/61 3/60 ns
BMD, Bone Mineral Density; DXA, dual-energy X-ray absorptiometry; ns, not significant; SBMA, spinal and bulbar muscular atrophy.
Figure 1 (A) One patient showed a type 2 ‘saddleback’ pattern in the
standard V1-V2 precordial leads (fourth intercostal space). (B) Eighteen
of 20 biopsies showed myopathic changes together with neurogenic
atrophy.
Table 4 Clinical and muscle pathology features of patients with
spinal and bulbar muscular atrophy
Patient
Age at
onset
(year)
Age at
biopsy
(year)
CAGs
(nr)
ADL scale
grade at
biopsy
Muscle
pathology
1 45 61 47 2 II
2 46 43 42 1 I
3 50 57 45 2 II
4 64 71 44 1 III
5 41 45 47 0 II
6 37 44 50 1 III
7 46 55 48 1 III
8 24 28 44 1 I
9 29 39 47 1 III
10 49 55 45 2 III
11 48 51 44 1 II
12 35 38 50 0 III
13 50 52 44 1 III
14 54 54 44 0 II
15 52 56 41 2 III
16 58 70 45 2 II
17 70 80 42 1 III
18 68 68 45 1 II
19 45 57 46 2 III
20 50 59 47 2 I
ADL scale, activity of daily living scale (0: normal; 1: mild weakness of limb muscles,
climbs stairs easily but aware of weakness; 2: mild-to-moderate weakness, climbs
stairs with difficulty and generally uses a cane; 3: moderate-to-severe weakness, uses
a wheelchair most of the time or mostly recumbent); muscle pathology (type I, only
signs of neurogenic atrophy; type II, signs of neurogenic atrophy plus 1 or 2
myopathic changes; type III, signs of neurogenic atrophy plus 3 or more myopathic
changes); nr, number of triplets.
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DISCUSSION
The observation that polyQ-AR expression is elevated in lower
motor neurons—the vulnerable neuronal cell type in SBMA—
had led to the assumption that SBMA is a motor neuron
disease. However, several lines of evidence, ranging from cell
biology to clinical features, support SBMA as a multisystem dis-
order. We show a wider than known clinical involvement of
non-neural androgen-responsive tissues in patients with SBMA.
We found that more than 40% of patients with SBMA in our
cohort reported moderate or severe LUTS, three of them carry-
ing indwelling bladder catheters. This frequency ﬁgure is deﬁn-
itely higher than expected since the prevalence of LUTS has
been estimated to amount up to no more than 30% in a general
male population of the same age range.30 Videourodynamic
evaluation mostly pointed to a bladder outlet obstruction in
patients with severe urinary symptoms. While the age of these
respondents (median 66 years) would suggest benign prostatic
hyperplasia,31 these observations argue against such a diagnosis:
ultrasonography ruled out prostate enlargement; PSA values
were normal; cystourethrography was always unremarkable,
with a competent bladder neck regularly opening during mictur-
ition; two carriers of an indwelling bladder catheter had a
prostate-unrelated obstruction. The mechanisms through which
polyQ-AR could cause bladder obstruction is unclear, but andro-
gen insensitivity may be postulated. Low androgen levels have
been associated with a higher risk of bladder outlet obstruc-
tion,32 and hypogonadism represents a key factor bridging meta-
bolic syndrome and urinary symptoms.33 The ﬁnding of urinary
tract obstruction in SBMA is quite intriguing since an analogous
mechanism leading to renal failure and death has been observed
in the murine SBMA model, in which altered excitability of ele-
vator ani/bulbocavernosus muscles could contribute to urinary
obstruction.34 Since motor neurons to bulbocavernosus muscles,
originating from Onuf ’s nucleus, are protected from neurode-
generation,11 a similar cell-autonomous dysfunction of pelvic
ﬂoor muscles could be considered in patients with SBMA, given
the increasing literature supporting the idea of skeletal muscle
as a site of mutant AR toxicity.13 35–38 An autonomic dysfunc-
tion might be also involved. Patients affected with SBMA
usually do not report symptoms that may suggest autonomic
dysfunction; nevertheless, the subclinical involvement of both
the orthosympathetic and parasympathetic nervous systems has
been reported.39 Moreover, one single patient, carrying the
longest CAG repeat ever found (68 triplets), reported auto-
nomic dysfunctions such as decreased sweating and difﬁculties
with ejaculation.4 In our SBMA cohort, we have studied
Sympathetic Skin Response (SSR) and our preliminary ﬁndings
are consistent with a prolonged latency of the potential (unpub-
lished data).
Androgens act on bone metabolism, promoting periosteal
bone formation mostly during puberty,40 and reducing bone
resorption mostly during adult life.41 Indeed, hypogonadism
was found in about 15% of men with osteoporosis,40 and
patients with androgen insensitivity syndrome had decreased
BMD.42 43 About 40% of patients with SBMA in our cohort
showed low BMD mainly consistent with osteopenia. This
prevalence was not unexpected as osteopenia is reported in at
least 30% of men aged 50 years or older.44 45 In addition,
osteopenia and fractures are common in patients with muscular
atrophy,46–48 and increased bone resorption was detected in
patients with amyotrophic lateral sclerosis.49 We were surprised
by the relatively well-preserved spinal bone density compared
with the increased frequency of low femoral BMD, this latter
being even higher than in controls. A possible explanation
might be that reduced mechanical load secondary to muscle
weakness in the lower limbs—the most frequent site of disease
onset—had led to femoral bone loss.50 However, the lack of
correlation between DXA measures and functional scores argues
against this hypothesis. Moreover, it would remain unexplained
why bone density is preserved at the lumbar level compared
with age-matched male patients.44 45 The potential to evaluate
contributions of 25-hydroxyvitamin D deﬁciency is limited,
since no difference in BMD was observed between patients
with normal versus deﬁcient serum levels. Taken together, these
ﬁndings suggest the need for a careful bone health follow-up in
SBMA.
As previously described,15 there was no sign of structural
cardiomyopathy in our patients. A recent study reported a
high prevalence (11.8%) of Brugada-like ECG in a Japanese
population with SBMA, ascribed to a downregulation of the
SCN5A gene leading to sodium current reduction in the myo-
cardium.16 Of note, two patients had symptomatic Brugada
syndrome and died suddenly during follow-up. In our study,
we found non-diagnostic Brugada ECG abnormalities in three
patients (4%), mostly recorded in non-conventional upward
right precordial leads (third intercostal space), and not asso-
ciated with any relevant symptom. This prevalence is signiﬁ-
cantly lower than that reported in the Japanese study: the
discrepancy may be explained by the different ethnic back-
ground, the Brugada syndrome more frequent in the Asian
than the Caucasian population. Although no sudden cardiac
death events were observed in our cohort, our ﬁndings
conﬁrm the need for accurate and serial ECG evaluation to
identify Brugada-like repolarisation abnormalities. Thus, our
suggestion is to record lead V1-V2 over the III and II intercos-
tal space, to enhance the sensitivity for detection of Brugada
like ECG-changes. Patients presenting with a Brugada-like ECG
should be prudently advised to prevent and correct hypokal-
aemia, to promptly treat a fever >38° by antipyretic therapy,
and to use caution in taking antiarrhythmic drugs known to
worsen ECG abnormalities and potentially trigger ventricular
tachyarrhythmias in Brugada syndrome.
Twenty patients in our cohort underwent skeletal muscle
biopsy during their diagnostic workup. As in our previous
study conducted on a smaller series,13 we detected myogenic
changes in addition to neurogenic atrophy in the majority of
biopsies. We did not conﬁrm any relationship of motor disabil-
ity with the amount of myogenic pathology, even if, interest-
ingly, the highest CAG repeat number (50) was measured in
two mildly symptomatic patients with type III muscle
pathology.
Hormonal and biochemical proﬁles were overall consistent
with previous reports.2 3 36 51 52 We conﬁrmed elevated CK
levels in nearly all cases. Although testosterone, LH and FSH
were generally normal, in one-third of cases we calculated a
slightly-to-markedly increased ASI, reﬂecting androgen resist-
ance. Our patients with SBMA frequently had elevated total
cholesterol, triglycerides and fasting glucose, underlying a
partial metabolic syndrome. Given the age range of our patients,
we cannot establish to what extent androgen insensitivity rather
than age per se contributes to these metabolic abnormalities.
Previously, Rhodes et al.3 found mean cholesterol and glucose
levels in their cohort of patients with SBMA similar to a
national sample of age-matched men. In our patients, we did
not note any age-dependent change of biochemical parameters.
Whatever the mechanism, the need to treat diabetes/glucose
intolerance and hyperlipidaemia raises some questions. For
instance, the use of statins may be challenging. Statin-induced
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muscle toxicity is well documented,53 and there are no pub-
lished data on safety of statins in SBMA. A similar therapeutic
issue may be recognised for ED, which was observed at variable
degrees in every patient in our cohort. The lack of scientiﬁc evi-
dence supporting the efﬁcacy and safety of medications for ED
or other disorders related to SBMA highlights the need for clin-
ical trials of symptomatic agents along with those for disease-
modifying treatments.
We provided evidence of a wide non-neural clinical pheno-
type in SBMA. While the mechanism of the polyQ-AR damage
remains to be established, that is, whether polyQ expansion in
AR causes disease through a loss of function or a gain of toxic
function, more effort should be made to set up comprehensive,
multidisciplinary protocols for patients affected with SBMA
and, possibly, for symptomatic female carriers.
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